AstraZeneca/FibroGen’s Roxadustat Comparison To ESAs In Anemia May By Clarified At FDA Advisory Cmte.

 
• By Cathy Kelly
  
ICER Finds Roxadustat May Be Cost Saving In Non-Dialysis Patients But There's 'High' Degree Of Uncertainty
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers